Overview / Abstract: |
This three-part webcast series is targeted to medical oncologists, molecular pathologists, and other clinicians who are involved in diagnosis and treatment of HER2+ gastric cancer. Moderated expertly by the series Chair, Dr. David Ilson from Memorial Sloan Kettering, our knowledgeable faculty will examine the latest testing guidelines and clinical trial data, exploring the burgeoning evidentiary base in support of an expanded role for antibody-drug conjugates in oncology, and specifically in HER2+ gastric cancer. |
Expiration |
Dec 31, 2021 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
Format |
Online, Webinar / Webcast / Video |
Credits / Hours |
1.75 |
Accreditation |
ACCME |
Is This Activity Certified for "Live" Credit? |
YES |
Presenters / Authors / Faculty |
David H. Ilson, MD, PhD Michael F. Press, MD, PhD Kohei Shitara, MD Yelena Y. Janjigian, MD |
Sponsors / Supporters / Grant Providers |
Supported through an Independent Educational Grant from AstraZeneca and Daiichi Sankyo. |
Keywords / Search Terms |
CE Concepts medical oncologists, molecular pathologists, HER2+, HER2+ Gastric Cancer, Gastric Cancer, antibody-drug conjugates in oncology, Oncology, Gastric oncology, Gastric Free CE CME Live CE CME |